Results 191 to 200 of about 112,843 (300)

Regulatory B cell expansion and type 1 innate lymphoid cell suppression characterise immune modulation in paediatric lupus nephritis. [PDF]

RMD Open
Lin CY, Chien JW, Lin KH, Hsiao KH, Tien YC, Su TC, Wei CC, Fu LS, Yang KD, Kao JK, Tsai YG.   +10 more
europepmc   +1 more source

RENAL‐CHIP: Rejection Evaluation via Non‐Invasive Analysis of Circulating Podocytes With Herringbone‐Chip Isolation Platform

Advanced Science, Volume 13, Issue 31, 4 June 2026.
RENAL‐CHIP converts 1 mL of peripheral blood into a biopsy‐equivalent readout of renal‐allograft fate. By magnetic capture and release of donor‐derived circulating podocytes through a herringbone microfluidic chip, 84% capture, 96% release and single‐cell RNA evidence of rejection‐specific immunity are achieved.
Juan Song, Yilong Liu, Zeyuan Zheng, Ming Zhu, Yuning Zou, Pei Liu, Yue Zheng, Xiyuan Yu, Jianzhong Zheng, Chen Shao, Huimin Zhang, Chaoyong Yang   +11 more
wiley   +1 more source

Correction: MiR-1290 in natural killer cell derived extracellular vesicles: a pathogenic mediator of lupus nephritis and therapeutic target for th17 regulation. [PDF]

J Nanobiotechnology
Cheng C, Su H, Li X, Li R, Yang Q, Guan T, Li M, Ou C.   +7 more
europepmc   +1 more source

Single‐Cell RNA Sequencing Informs Precision Targeting of Monogenic Lupus Associated With IKZF1 Haploinsufficiency

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1231-1244, June 2026.
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng, Yejun Tan, Zhaoling Wang, Yanjie Qian, Qian Ma, Danping Shen, Meiping Lu   +6 more
wiley   +1 more source

Chronic Nephritis [PDF]

Postgraduate Medical Journal, 1937
openaire   +2 more sources

Beyond renal response: sustained systemic disease control protects against adverse long-term outcomes in lupus nephritis. [PDF]

Lupus Sci Med
Drougkas K, Katechis S, Kostopoulou M, Tsalapaki C, Flouda S, Pappa M, Bakula M, Padjen I, Nikoloudaki M, Konstantopoulou P, Moustakas G, Vassilopoulos D, Bertsias G, Voulgari PV, Boumpas DT, Fanouriakis A.   +15 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1258-1267, June 2026.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Acute Kidney Injury, Fever, and Dark Urine in a Kidney Transplant Recipient. [PDF]

Kidney360
Rosenstiel PE, Goyal A.
europepmc   +1 more source

5‐Methylcytosine Analysis of miRNAs in Minimal Change Disease

Biotechnology and Applied Biochemistry, Volume 73, Issue 3, Page 1137-1150, June 2026.
ABSTRACT Minimal change disease (MCD) is a glomerular disorder, which is the most common cause of nephrotic syndrome in children. Additionally, the prevalence of MCD in adults has been increasing in recent years. During protein synthesis, noncoding RNAs can be regulated through a variety of modifications, which helps preserve biological diversity and ...
Huiyi Zeng, Dandan Li, Yunyi Li, Chen Yun, Xinzhou Zhang, Wenyu Gong, Mengyun Xiao, Haitao Li, Zhipeng Zeng, Ruqi Tan, Yishen Yang, Shaodong Luan, Yong Dai, Lianghong Yin, Donge Tang   +14 more
wiley   +1 more source

Safety and Efficacy of Obinutuzumab in Treating Lupus Nephritis: A Systematic Review. [PDF]

Immun Inflamm Dis
Arif Z, Ali H, Siddiqui E, Naeem S, Amin MHJ.   +4 more
europepmc   +1 more source